Literature DB >> 20163878

Reduction of cell proliferation and potentiation of Fas-induced apoptosis by the selective kappa-opioid receptor agonist U50 488 in the multiple myeloma LP-1 cells.

Céline Kerros1, Isabelle Brood, Brigitte Sola, Philippe Jauzac, Stéphane Allouche.   

Abstract

As opioid receptors modulate proliferation and apoptosis of immune cells, we hypothesized that they could reduce malignant haematopoietic cells. After screening, we selected the human multiple myeloma LP-1 cells which express mu- (MOP-) and kappa-opioid receptors (KOP-R). U50 488 produces a modest but significant decrease in viability associated with an arrest in the G0/G1 phase, but not antagonized by NorBNI and not associated with modulation of p21(Cip1), p27(Kip1) or p53 expression. In contrast, no effect was observed with dynorphin, U69 593 and morphine. In conclusion, the anti-proliferative effects of U50 488 are not mediated by KOP-R in the LP-1 cells. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20163878     DOI: 10.1016/j.jneuroim.2010.01.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

Review 1.  Meta-analysis of the effects of beta blocker on survival time in cancer patients.

Authors:  Chel Hun Choi; Taejong Song; Tae Hyun Kim; Jun Kuk Choi; Jin-Young Park; Aera Yoon; Yoo-Young Lee; Tae-Joong Kim; Duk-Soo Bae; Jeong-Won Lee; Byoung-Gie Kim
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-27       Impact factor: 4.553

2.  Mu-opioid receptor densities are depleted in regions implicated in agonistic and sexual behavior in male European starlings (Sturnus vulgaris) defending nest sites and courting females.

Authors:  Cynthia A Kelm; Robin M Forbes-Lorman; Catherine J Auger; Lauren V Riters
Journal:  Behav Brain Res       Date:  2010-12-13       Impact factor: 3.332

Review 3.  A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins.

Authors:  Elad Neeman; Oded Zmora; Shamgar Ben-Eliyahu
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

Review 4.  Exploiting the critical perioperative period to improve long-term cancer outcomes.

Authors:  Maya Horowitz; Elad Neeman; Eran Sharon; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2015-01-20       Impact factor: 66.675

Review 5.  [Interaction of anesthetics and analgesics with tumor cells].

Authors:  A Bundscherer; M Malsy; D Bitzinger; B M Graf
Journal:  Anaesthesist       Date:  2014-04       Impact factor: 1.041

6.  Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?

Authors:  Li Jiang; Alpa M Nick; Anil K Sood
Journal:  Curr Anesthesiol Rep       Date:  2015-09

7.  Mechanism Governing Human Kappa-Opioid Receptor Expression under Desferrioxamine-Induced Hypoxic Mimic Condition in Neuronal NMB Cells.

Authors:  Jennifer Babcock; Alberto Herrera; George Coricor; Christopher Karch; Alexander H Liu; Aida Rivera-Gines; Jane L Ko
Journal:  Int J Mol Sci       Date:  2017-01-20       Impact factor: 5.923

8.  Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study.

Authors:  Hye-In Jang; Soo-Hyun Lim; Yoo-Young Lee; Tae-Joong Kim; Chel Hun Choi; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  Obstet Gynecol Sci       Date:  2017-03-16

9.  Dopamine D3 receptor dysfunction prevents anti-nociceptive effects of morphine in the spinal cord.

Authors:  Kori L Brewer; Christine A Baran; Brian R Whitfield; A Marley Jensen; Stefan Clemens
Journal:  Front Neural Circuits       Date:  2014-06-11       Impact factor: 3.492

10.  Delta-opioid receptor analgesia is independent of microglial activation in a rat model of neuropathic pain.

Authors:  Joanna Mika; Katarzyna Popiolek-Barczyk; Ewelina Rojewska; Wioletta Makuch; Katarzyna Starowicz; Barbara Przewlocka
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.